Novartis AG ADR (NVS)vsSS Innovations International Inc. Common Stock (SSII)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
SSII
SS Innovations International Inc. Common Stock
$3.31
+0.30%
HEALTHCARE · Cap: $645.24M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 108082% more annual revenue ($56.69B vs $52.41M). NVS leads profitability with a 22.5% profit margin vs -23.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SSII
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+86.9%
Fair Value
$25.38
Current Price
$3.31
$22.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 39.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 12.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SSII
The strongest argument for SSII centers on Revenue Growth, Debt/Equity. Revenue growth of 39.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SSII
The primary concerns for SSII are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a value stock while SSII is a hypergrowth play — different risk/reward profiles.
SSII carries more volatility with a beta of 0.58 — expect wider price swings.
SSII is growing revenue faster at 39.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 22/100), backed by strong 22.5% margins. SSII offers better value entry with a 86.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →SS Innovations International Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?